ALHC vs MRNA: fair value comparison
Alignment Healthcare, Inc. and Moderna, Inc. · Updated 2026-10-19
ALHC is still awaiting a full valuation verdict under our six-validated-windows standard. MRNA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MRNA currently ranks higher by quality score.
| ALHC | MRNA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $8.28 | $218.01 |
| 12-month range | $7.54–$24.56 | $22.36–$236.50 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #198 of 301 Healthcare | #197 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ALHC fair value analysis · MRNA fair value analysis